Scientists test virus to target advanced cancers
NCT ID NCT05165433
Summary
This early-stage study tested the safety of a new two-part treatment for advanced cancers that have spread. The treatment combines a specially engineered virus designed to attack tumors with an existing immunotherapy drug. It involved 14 patients whose cancer had progressed despite standard treatments, aiming to find a safe dose and see if the combination shows early signs of working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Moffitt-Advent Health Clinical Research Unit
Celebration, Florida, 34747, United States
-
Perelman Center of Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Providence Medical Foundation
Santa Monica, California, 90404, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Lancashire, L7 8YA, United Kingdom
-
UCLA
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.